中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 38 Issue 1
Jan.  2022
Turn off MathJax
Article Contents
Article Navigation >  Journal of Clinical Hepatology  > 2022  >  38(1): 42-49

Guidelines on the diagnosis and management of autoimmune hepatitis (2021)

DOI: 10.3760/cma.j.cn112138-20211112-00796
  • Received Date: 2021-12-25
  • Published Date: 2022-01-20
    Abstract
  • Autoimmune hepatitis (AIH) is characterized by elevated serum aminotransferase and immunoglobulin G levels, seropositive results for autoantibodies and moderate to severe interface hepatitis in histologic findings. It will be most helpful in improving survival and life quality, if patients are diagnosed in the early stage and treated appropriately, which also helps relieve social medical burdens. Chinese consensus on the diagnosis and management of autoimmune hepatitis (2015) has contributed to standardizing the diagnosis and treatment of AIH. On the basis of the first consensus, at the end of 2021, under the organization of Chinese Society of Hepatology, experts devise this guide with latest advances aiming to further improve the level of diagnosis and management of autoimmune hepatitis.

     

    • FullText(HTML)
  • loading
    • References(47)
  • [1]
    中华医学会肝病学分会, 中华医学会消化病学分会, 中华医学会感染病学分会. 自身免疫性肝炎诊断和治疗共识(2015)[J]. 临床肝胆病杂志, 2016, 32(1): 9-22. DOI: 10.3969/j.issn.1001-5256.2016.01.002.
    [2]
    de BOER YS, GERUSSI A, van den BRAND FF, et al. Association between black race and presentation and liver-related outcomes of patients with autoimmune hepatitis[J]. Clin Gastroenterol Hepatol, 2019, 17(8): 1616-1624. e2. DOI: 10.1016/j.cgh.2018.11.028.
    [3]
    WANG QX, YAN L, MA X. Autoimmune hepatitis in the Asia-Pacific Area[J]. J Clin Transl Hepatol, 2018, 6(1): 48-56. DOI: 10.14218/JCTH.2017.00032.
    [4]
    LAMBA M, NGU JH, STEDMAN C. Trends in incidence of autoimmune liver diseases and increasing incidence of autoimmune hepatitis[J]. Clin Gastroenterol Hepatol, 2021, 19(3): 573-579. e1. DOI: 10.1016/j.cgh.2020.05.061.
    [5]
    TANAKA A, MORI M, MATSUMOTO K, et al. Increase trend in the prevalence and male-to-female ratio of primary biliary cholangitis, autoimmune hepatitis, and primary sclerosing cholangitis in Japan[J]. Hepatol Res, 2019, 49(8): 881-889. DOI: 10.1111/hepr.13342.
    [6]
    TANAKA A. Autoimmune Hepatitis: 2019 Update[J]. Gut Liver, 2020, 14(4): 430-438. DOI: 10.5009/gnl19261.
    [7]
    LI Y, YAN L, WANG R, et al. Serum immunoglobulin G levels predict biochemical and histological remission of autoimmune hepatitis type 1: A single-center experience and literature review[J]. Clin Rev Allergy Immunol, 2021. DOI: 10.1007/s12016-021-08833-w.[Online ahead of print]
    [8]
    WANG QX, JIANG WJ, MIAO Q, et al. Clinical and histological features of autoantibody-negative autoimmune hepatitis in Chinese patients: A single center experience[J]. J Dig Dis, 2013, 14(4): 175-180. DOI: 10.1111/1751-2980.12022.
    [9]
    DHALIWAL HK, HOEROLDT BS, DUBE AK, et al. Long-term prognostic significance of persisting histological activity despite biochemical remission in autoimmune hepatitis[J]. Am J Gastroenterol, 2015, 110(7): 993-999. DOI: 10.1038/ajg.2015.139.
    [10]
    GURUNG A, ASSIS DN, MCCARTY TR, et al. Histologic features of autoimmune hepatitis: A critical appraisal[J]. Hum Pathol, 2018, 82: 51-60. DOI: 10.1016/j.humpath.2018.07.014.
    [11]
    MIAO Q, BIAN Z, TANG R, et al. Emperipolesis mediated by CD8 T cells is a characteristic histopathologic feature of autoimmune hepatitis[J]. Clin Rev Allergy Immunol, 2015, 48(2-3): 226-235. DOI: 10.1007/s12016-014-8432-0.
    [12]
    STRAVITZ RT, LEFKOWITCH JH, FONTANA RJ, et al. Autoimmune acute liver failure: Proposed clinical and histological criteria[J]. Hepatology, 2011, 53(2): 517-526. DOI: 10.1002/hep.24080
    [13]
    TAKAHASHI A, ARINAGA-HINO T, OHIRA H, et al. Autoimmune hepatitis in Japan: Trends in a nationwide survey[J]. J Gastroenterol, 2017, 52(5): 631-640. DOI: 10.1007/s00535-016-1267-0.
    [14]
    ALVAREZ F, BERG PA, BIANCHI FB, et al. International Autoimmune Hepatitis Group Report: Review of criteria for diagnosis of autoimmune hepatitis[J]. J Hepatol, 1999, 31(5): 929-938. DOI: 10.1016/s0168-8278(99)80297-9.
    [15]
    HENNES EM, ZENIYA M, CZAJA AJ, et al. Simplified criteria for the diagnosis of autoimmune hepatitis[J]. Hepatology, 2008, 48(1): 169-176. DOI: 10.1002/hep.22322.
    [16]
    QIU D, WANG Q, WANG H, et al. Validation of the simplified criteria for diagnosis of autoimmune hepatitis in Chinese patients[J]. J Hepatol, 2011, 54(2): 340-347. DOI: 10.1016/j.jhep.2010.06.032.
    [17]
    GALASKI J, WEILER-NORMANN C, SCHAKAT M, et al. Update of the simplified criteria for autoimmune hepatitis: Evaluation of the methodology for immunoserological testing[J]. J Hepatol, 2021, 74(2): 312-320. DOI: 10.1016/j.jhep.2020.07.032.
    [18]
    CHEN RL, WANG QX, MA X. Precision medicine for autoimmune hepatitis[J]. J Dig Dis, 2019, 20(7): 331-337. DOI: 10.1111/1751-2980.12786.
    [19]
    WANG Z, SHENG L, YANG Y, et al. The management of autoimmune hepatitis patients with decompensated cirrhosis: Real-world experience and a comprehensive review[J]. Clin Rev Allergy Immunol, 2017, 52(3): 424-435. DOI: 10.1007/s12016-016-8583-2.
    [20]
    PEISELER M, LIEBSCHER T, SEBODE M, et al. Efficacy and limitations of budesonide as a second-line treatment for patients with autoimmune hepatitis[J]. Clin Gastroenterol Hepatol, 2018, 16(2): 260-267. e1. DOI: 10.1016/j.cgh.2016.12.040.
    [21]
    MANNS MP, WOYNAROWSKI M, KREISEL W, et al. Budesonide induces remission more effectively than prednisone in a controlled trial of patients with autoimmune hepatitis[J]. Gastroenterology, 2010, 139(4): 1198-1206. DOI: 10.1053/j.gastro.2010.06.046.
    [22]
    WOYNAROWSKI M, NEMETH A, BARUCH Y, et al. Budesonide versus prednisone with azathioprine for the treatment of autoimmune hepatitis in children and adolescents[J]. J Pediatr, 2013, 163(5): 1347-1353. e1. DOI: 10.1016/j.jpeds.2013.05.042.
    [23]
    EFE C, HAGSTRÖM H, YTTING H, et al. Efficacy and safety of mycophenolate mofetil and tacrolimus as second-line therapy for patients with autoimmune hepatitis[J]. Clin Gastroenterol Hepatol, 2017, 15(12): 1950-1956. e1. DOI: 10.1016/j.cgh.2017.06.001.
    [24]
    LIBERAL R, de BOER YS, ANDRADE RJ, et al. Expert clinical management of autoimmune hepatitis in the real world[J]. Aliment Pharmacol Ther, 2017, 45(5): 723-732. DOI: 10.1111/apt.13907.
    [25]
    DE LEMOS-BONOTTO M, VALLE-TOVO C, COSTABEBER AM, et al. A systematic review and meta-analysis of second-line immunosuppressants for autoimmune hepatitis treatment[J]. Eur J Gastroenterol Hepatol, 2018, 30(2): 212-216. DOI: 10.1097/MEG.0000000000001019.
    [26]
    HANOUNEH M, RITCHIE MM, ASCHA M, et al. A review of the utility of tacrolimus in the management of adults with autoimmune hepatitis[J]. Scand J Gastroenterol, 2019, 54(1): 76-80. DOI: 10.1080/00365521.2018.1551498.
    [27]
    MONTANO-LOZA AJ, BHANJI RA, WASILENKO S, et al. Systematic review: Recurrent autoimmune liver diseases after liver transplantation[J]. Aliment Pharmacol Ther, 2017, 45(4): 485-500. DOI: 10.1111/apt.13894.
    [28]
    MACK CL, ADAMS D, ASSIS DN, et al. Diagnosis and management of autoimmune hepatitis in adults and children: 2019 practice guidance and guidelines from the American Association for the Study of Liver Diseases[J]. Hepatology, 2020, 72(2): 671-722. DOI: 10.1002/hep.31065.
    [29]
    KERKAR N, YANNI G. 'De novo' and 'recurrent' autoimmune hepatitis after liver transplantation: A comprehensive review[J]. J Autoimmun, 2016, 66: 17-24. DOI: 10.1016/j.jaut.2015.08.017.
    [30]
    MORIYAMA T, NISHⅡ R, PEREZ-ANDREU V, et al. NUDT15 polymorphisms alter thiopurine metabolism and hematopoietic toxicity[J]. Nat Genet, 2016, 48(4): 367-373. DOI: 10.1038/ng.3508.
    [31]
    LOHSE AW, SEBODE M, J∅RGENSEN MH, et al. Second-line and third-line therapy for autoimmune hepatitis: A position statement from the European Reference Network on Hepatological Diseases and the International Autoimmune Hepatitis Group[J]. J Hepatol, 2020, 73(6): 1496-1506. DOI: 10.1016/j.jhep.2020.07.023.
    [32]
    XU Q, SHENG L, BAO H, et al. Evaluation of transient elastography in assessing liver fibrosis in patients with autoimmune hepatitis[J]. J Gastroenterol Hepatol, 2017, 32(3): 639-644. DOI: 10.1111/jgh.13508.
    [33]
    HARTL J, EHLKEN H, SEBODE M, et al. Usefulness of biochemical remission and transient elastography in monitoring disease course in autoimmune hepatitis[J]. J Hepatol, 2018, 68(4): 754-763. DOI: 10.1016/j.jhep.2017.11.020.
    [34]
    FIX OK, BLUMBERG EA, CHANG KM, et al. American Association for the Study of Liver Diseases Expert Panel consensus statement: Vaccines to prevent coronavirus disease 2019 infection in patients with liver disease[J]. Hepatology, 2021, 74(2): 1049-1064. DOI: 10.1002/hep.31751.
    [35]
    CORNBERG M, BUTI M, EBERHARDT CS, et al. EASL position paper on the use of COVID-19 vaccines in patients with chronic liver diseases, hepatobiliary cancer and liver transplant recipients[J]. J Hepatol, 2021, 74(4): 944-951. DOI: 10.1016/j.jhep.2021.01.032.
    [36]
    BIEWENGA M, INDERSON A, TUSHUIZEN ME, et al. Early predictors of short-term prognosis in acute and acute severe autoimmune hepatitis[J]. Liver Transpl, 2020, 26(12): 1573-1581. DOI: 10.1002/lt.25906.
    [37]
    ZACHOU K, ARVANITI P, AZARIADIS K, et al. Prompt initiation of high-dose i. v. corticosteroids seems to prevent progression to liver failure in patients with original acute severe autoimmune hepatitis[J]. Hepatol Res, 2019, 49(1): 96-104. DOI: 10.1111/hepr.13252.
    [38]
    YEOMAN AD, WESTBROOK RH, ZEN Y, et al. Prognosis of acute severe autoimmune hepatitis (AS-AIH): The role of corticosteroids in modifying outcome[J]. J Hepatol, 2014, 61(4): 876-882. DOI: 10.1016/j.jhep.2014.05.021.
    [39]
    REDDY HG, SCHNEIDER BJ, TAI AW. Immune checkpoint inhibitor-associated colitis and hepatitis[J]. Clin Transl Gastroenterol, 2018, 9(9): 180. DOI: 10.1038/s41424-018-0049-9.
    [40]
    CZAJA AJ. Immune inhibitory proteins and their pathogenic and therapeutic implications in autoimmunity and autoimmune hepatitis[J]. Autoimmunity, 2019, 52(4): 144-160. DOI: 10.1080/08916934.2019.1641200.
    [41]
    LOOMBA R, LIANG TJ. Hepatitis B reactivation associated with immune suppressive and biological modifier therapies: Current concepts, management strategies, and future directions[J]. Gastroenterology, 2017, 152(6): 1297-1309. DOI: 10.1053/j.gastro.2017.02.009.
    [42]
    LIN XQ, SHENG L, XIAO X, et al. Analysis of clinical diagnosis and treatment in chronic hepatitis B combined with autoimmune hepatitis[J]. Chin J Hepatol, 2020, 28(4): 351-356. DOI: 10.3760/cma.j.cn501113-20190120-00020.

    林小钦, 盛黎, 肖潇, 等. 慢性乙型肝炎合并自身免疫性肝炎的临床诊治分析[J]. 中华肝脏病杂志, 2020, 28(4): 351-356. DOI: 10.3760/cma.j.cn501113-20190120-00020.
    [43]
    MIELI-VERGANI G, VERGANI D, BAUMANN U, et al. Diagnosis and management of pediatric autoimmune liver disease: ESPGHAN hepatology committee position statement[J]. J Pediatr Gastroenterol Nutr, 2018, 66(2): 345-360. DOI: 10.1097/MPG.0000000000001801.
    [44]
    NASTASIO S, SCIVERES M, MATARAZZO L, et al. Long-term follow-up of children and young adults with autoimmune hepatitis treated with cyclosporine[J]. Dig Liver Dis, 2019, 51(5): 712-718. DOI: 10.1016/j.dld.2018.10.018.
    [45]
    EFE C, TAⅡ HA, YTTING H, et al. Tacrolimus and mycophenolate mofetil as second-line therapies for pediatric patients with autoimmune hepatitis[J]. Dig Dis Sci, 2018, 63(5): 1348-1354. DOI: 10.1007/s10620-018-5011-x.
    [46]
    WANG Q, QIU D, MA X. Early normalisation of aminotransferase predicts complete biochemical remission in autoimmune hepatitis patients[J]. Aliment Pharmacol Ther, 2011, 34(1): 107-109. DOI: 10.1111/j.1365-2036.2011.04690.x.
    [47]
    TANSEL A, KATZ LH, EL-SERAG HB, et al. Incidence and determinants of hepatocellular carcinoma in autoimmune hepatitis: A systematic review and Meta-analysis[J]. Clin Gastroenterol Hepatol, 2017, 15(8): 1207-1217. e4. DOI: 10.1016/j.cgh.2017.02.006.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(1)  / Tables(4)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (5773) PDF downloads(1750) Cited by()
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[]YesterdayPV[]TodayIP[]TodayPV[]Online[]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return